Women with cystic fibrosis (CF) who continue on CFTR modulator therapy during pregnancy show stable health and no increase in birth complications, according to a new review. At the same time, published case reports and small studies have found that intentionally treating a baby with CF before birth…
News
In an interview study, adults with cystic fibrosis who also developed diabetes reported that using a new type of insulin delivery system led to wide-ranging improvements in their daily lives, including easier blood sugar management and needed weight gain. For many, the use of the hybrid closed-loop system —…
Adults with cystic fibrosis (CF) and their healthcare providers generally agree that those living with stable disease while on CFTR modulator therapy could wait longer between routine clinic visits, according to surveys. Doctors of adult CF patients were more comfortable with lower lung function thresholds and fewer required visits…
CFTR modulators, a class of medications used to treat cystic fibrosis (CF), were associated with reductions in the airway burden of Pseudomonas aeruginosa and in the number of bacterial clusters over time, but large aggregates persisted, a study suggests. While CFTR modulator use was linked to a lower overall…
Children and adolescents with cystic fibrosis (CF) showed increased oxidative stress, which can cause cellular damage, higher inflammation, and reduced activity in the nervous system that helps regulate heart rate, even when their lung disease was mild, a study reports. The study also found that, in the study population…
A new model based on body composition and hand grip strength may help clinicians identify children with cystic fibrosis (CF) at risk of rapid weight gain or weight loss after starting Trikafta (elexacaftor/tezacaftor/ivacaftor), a new study suggests. In 27 children treated with Trikafta, researchers found that weight responses…
Parent caregivers of people with cystic fibrosis (CF) want a tailored, internet-delivered resource offering mental health support, disease education, and connection with other CF families, a study in Canada showed. Researchers said the information gained from the interview-based study will be used “to develop an accessible, tailored, Internet-delivered resource…
People with cystic fibrosis (CF) in Canada are a step closer to gaining public access to Alyftrek, a once-daily triple-combination therapy approved for patients ages 6 and older with at least one mutation that’s responsive to the therapy. Vertex Pharmaceuticals, which markets Alyftrek, has signed a letter…
Arcturus Therapeutics is partnering with Thermo Fisher Scientific to support the development of ARCT-032, Arcturus’ experimental inhaled therapy for cystic fibrosis (CF). Under the agreement, Thermo Fisher will provide Arcturus with manufacturing and clinical trial support for a planned Phase 3 study testing ARCT-032. And if the…
Trikafta (elexacaftor, tezacaftor, and ivacaftor) may improve blood sugar control in people with cystic fibrosis (CF), including those with CF-related diabetes, or CFRD, a study showed. After about one year of treatment, patients with CFRD showed clinically meaningful reductions in glycated hemoglobin (HbA1c), a measure of average blood sugar…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.